Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early diagnostic marker panel determination for microarray based clinical studies.

Jochen Jaeger1, Dieter Weichenhan, Boris Ivandic

  • 1Max Planck Institute for Molecular Genetics, Berlin. jochen.jaeger@molgen.mpg.de

Statistical Applications in Genetics and Molecular Biology
|May 2, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Blood advances·2026
Same author

GLYATL1 is associated with metabolic and epigenetic changes and with endocrine resistance in luminal breast cancer.

Clinical epigenetics·2026
Same author

ID3 deficiency alters chromatin accessibility at DSB sites and enhances vulnerability to HDAC inhibition.

International journal of cancer·2026
Same author

Role of MNX1-mediated histone modifications and PBX gene family in MNX1-induced leukemogenesis.

Scientific reports·2026
Same author

<b>mhn</b>: a Python package for analyzing cancer progression with Mutual Hazard Networks.

Bioinformatics advances·2026
Same author

Integration of high-throughput proteomic data and complementary omics layers with PriOmics.

Genome research·2025
Same journal

Annealed variational mixtures for disease subtyping and biomarker discovery.

Statistical applications in genetics and molecular biology·2026
Same journal

Performance of the permutation test approach with base calling errors for detecting changes in variant allele frequencies in ctDNA for a single patient.

Statistical applications in genetics and molecular biology·2026
Same journal

BLOG: Bayesian longitudinal omics with group constraints.

Statistical applications in genetics and molecular biology·2026
Same journal

AI-driven risk prediction and categorization in cystic fibrosis leveraging AttentiveLSTM and Fox Wolf Optimizer.

Statistical applications in genetics and molecular biology·2026
Same journal

Perfect collinearity not created equal: measuring and visualizing the severity of multi-collinearity of modern omics data.

Statistical applications in genetics and molecular biology·2026
Same journal

Corrigendum to: Choice of baseline hazards in joint modeling of longitudinal and time-to-event cancer survival data.

Statistical applications in genetics and molecular biology·2025
See all related articles

This study introduces a cost-effective two-phase design for gene expression studies, called early marker panel determination (EMPD). EMPD uses fewer genome-wide microarrays, making predictive clinical trials more affordable with minimal performance loss.

Area of Science:

  • Biostatistics
  • Genomics
  • Translational Medicine

Background:

  • Predictive clinical studies often rely on genome-wide gene expression analysis, which can be prohibitively expensive.
  • Current methodologies necessitate extensive use of costly technologies like microarrays across large patient cohorts.
  • There is a need for cost-efficient strategies in gene expression profiling for clinical applications.

Purpose of the Study:

  • To introduce and evaluate a novel, cost-efficient two-phase design for predictive clinical gene expression studies: early marker panel determination (EMPD).
  • To assess the performance trade-offs between EMPD and traditional genome-wide microarray approaches.
  • To investigate the relationship between the number of Phase-1 patients and the required number of marker genes in Phase-2.

Main Methods:

Related Experiment Videos

  • Phase-1: Genome-wide microarrays are used on a small subset of patient samples to identify a preliminary panel of marker genes.
  • Phase-2: Expression levels of the selected marker genes are measured in a larger patient cohort using less expensive methods to build a predictive classification model.
  • Comparative analysis: EMPD performance is compared against designs utilizing genome-wide microarrays for all patients.

Main Results:

  • Analysis of five public datasets indicates that 16 patients per group in Phase-1 are sufficient for selecting a 10-gene marker panel.
  • The early marker panel determination strategy results in only marginal compromise in final predictive model performance.
  • A trade-off exists between the number of patients in Phase-1 and the number of marker genes needed in Phase-2.

Conclusions:

  • The early marker panel determination (EMPD) design offers a cost-efficient alternative for predictive clinical gene expression studies.
  • EMPD significantly reduces the reliance on expensive genome-wide microarrays, making large-scale clinical trials more feasible.
  • The proposed two-phase approach balances cost reduction with acceptable performance, supported by empirical data from multiple datasets.